• 제목/요약/키워드: Breast Disease

검색결과 809건 처리시간 0.027초

Prognostic factors in breast cancer with extracranial oligometastases and the appropriate role of radiation therapy

  • Yoo, Gyu Sang;Yu, Jeong Il;Park, Won;Huh, Seung Jae;Choi, Doo Ho
    • Radiation Oncology Journal
    • /
    • 제33권4호
    • /
    • pp.301-309
    • /
    • 2015
  • Purpose: To identify prognostic factors for disease progression and survival of patients with extracranial oligometastatic breast cancer (EOMBC), and to investigate the role of radiation therapy (RT) for metastatic lesions. Materials and Methods: We retrospectively reviewed the medical records of 50 patients who had been diagnosed with EOMBC following standard treatment for primary breast cancer initially, and received RT for metastatic lesions, with or without other systemic therapy between January 2004 and December 2008. EOMBC was defined as breast cancer with five or less metastases involving any organs except the brain. All patients had bone metastasis (BM) and seven patients had pulmonary, hepatic, or lymph node metastasis. Median RT dose applied to metastatic lesions was 30 Gy (range, 20 to 60 Gy). Results: The 5-year tumor local control (LC) and 3-year distant progression-free survival (DPFS) rate were 66.1% and 36.8%, respectively. High RT dose (${\geq}50Gy_{10}$) was significantly associated with improved LC. The 5-year overall survival (OS) rate was 49%. Positive hormone receptor status, pathologic nodal stage of primary cancer, solitary BM, and whole-lesion RT (WLRT), defined as RT whose field encompassed entire extent of disease, were associated with better survival. On analysis for subgroup of solitary BM, high RT dose was significantly associated with improved LC and DPFS, shorter metastasis-to-RT interval (${\leq}1month$) with improved DPFS, and WLRT with improved DPFS and OS, respectively. Conclusion: High-dose RT in solitary BM status and WLRT have the potential to improve the progression-free survival and OS of patients with EOMBC.

Incidence and Risk Factors for Leptomeningeal Carcinomatosis in Breast Cancer Patients with Parenchymal Brain Metastases

  • Jung, Jong-Myung;Kim, Sohee;Joo, Jungnam;Shin, Kyung Hwan;Gwak, Ho-Shin;Lee, Seung Hoon
    • Journal of Korean Neurosurgical Society
    • /
    • 제52권3호
    • /
    • pp.193-199
    • /
    • 2012
  • Objective : The objective of study is to evaluate the incidence of leptomeningeal carcinomatosis (LMC) in breast cancer patients with parenchymal brain metastases (PBM) and clinical risk factors for the development of LMC. Methods : We retrospectively analyzed 27 patients who had undergone surgical resection (SR) and 156 patients with whole brain radiation therapy (WBRT) as an initial treatment for their PBM from breast cancer in our institution and compared the difference of incidence of LMC according to clinical factors. The diagnosis of LMC was made by cerebrospinal fluid cytology and/or magnetic resonance imaging. Results : A total of 27 patients (14%) in the study population developed LMC at a median of 6.0 months (range, 1.0-50). Ten of 27 patients (37%) developed LMC after SR, whereas 17 of 156 (11%) patients who received WBRT were diagnosed with LMC after the index procedure. The incidence of LMC was significantly higher in the SR group compared with the WBRT group and the hazard ratio was 2.95 (95% confidence interval; 1.33-6.54, p<0.01). Three additional factors were identified in the multivariable analysis : the younger age group (<40 years old), the progressing systemic disease showed significantly increased incidence of LMC, whereas the adjuvant chemotherapy reduce the incidence. Conclusion : There is an increased risk of LMC after SR for PBM from breast cancer compared with WBRT. The young age (<40) and systemic burden of cancer in terms of progressing systemic disease without adjuvant chemotherapy could be additional risk factors for the development of LMC.

수유부의 유선질환을 의미하는 한의학 용어 연구 (A study of Korean Medicine Terminology that Meaning Breast Diseases During Breastfeeding)

  • 이선영;오준호;차웅석;김남일
    • 한국한의학연구원논문집
    • /
    • 제16권2호
    • /
    • pp.75-81
    • /
    • 2010
  • Objective : This study aims to clearly define the concept of Korean medicine terminology related with breast disease that occurs during breastfeeding. It attempts to suggest aguideline so that identical terms can be used to explain the medical conditions of breast-feeders from the perspective of oriental medicine. Method : This paper is based on what is recorded in medical books. It has organized the relations between the terms grounded on the analysis of similarities and differences in the concepts of the terms contained in them. The medical book chiefly used here was "Uibangyuchwi(醫方類聚)". To organize the terms, thesaurus was utilized. Result & Conclusion : The terminology of Korean medicine related with breast disease that occurs during breastfeeding is prescribed from the aspects of the causes, affected areas, or pathological conditions. The clinically typical terms of korean medicine are 'Tuyu(妬乳)' and 'Yuong(乳癰)'. The two are distinguished by whether one has systemic symptoms or not. If one has no systemic symptom, it is 'Chwiyu(吹乳)' or 'Tuyu', and these two are distinguished by whether one has 'Chang(瘡; sores)' or not. It is significant to organize the concepts of korean medicine terminology since they are directly related with treatments in the field.

Improved Long-term Survival with Contralateral Prophylactic Mastectomy among Young Women

  • Zeichner, Simon Blechman;Ruiz, Ana Lourdes;Markward, Nathan Joseph;Rodriguez, Estelamari
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제15권3호
    • /
    • pp.1155-1162
    • /
    • 2014
  • Background: Despite mixed survival data, the utilization of contralateral prophylactic mastectomy (CPM) for the prevention of a contralateral breast cancer (CBC) has increased significantly over the last 15 years, especially among women less than 40. We set out to look at our own experience with CPM, focusing on outcomes in women less than 40, the sub-population with the highest cumulative lifetime risk of developing CBC. With an extended follow-up, we hoped to demonstrate differences in the long-term disease free survival (DFS) and overall survival (OS) among groups who underwent the procedure (CPM) versus those that did not (NCPM). Materials and Methods: We performed a retrospective review of all breast cancer patients less than age 40 diagnosed at Mount Sinai Medical Center between January 1, 1980 and December 31, 2010 (n=481). Among these patients, 42 were identified as having undergone CPM, while 195 were confirmed as being CPM-free during the observation period. A univariate and multivariate analyses were performed. Results: The CPM group had a significantly higher percentage of patients who were diagnosed between 2000 and 2010 (95.2% vs 40%, p=0.0001). The CPM group had significantly smaller tumors (0-2cm.: 41.7% vs 24.8%, p=0.04). Among the entire group of patients, the overall five- and 10-year DFS were 81.3% and 73.3%, respectively. CPM was significantly associated [HR 2.35 (1.02, 5.41); p=0.046] with 10-year OS, although a similar effect was not observed for five-year OS. Conclusions: We found that CPM has increased dramatically over the last 15 years, especially among white women with locally advanced disease. In patients less than 40, who are thought to be at greatest cumulative risk of secondary breast cancer, CPM provided an OS advantage, regardless of genetics, tumor or patient characteristics, and which was only seen after 10 years of follow-up.

Clinical outcomes after sentinel lymph node biopsy in clinically node-negative breast cancer patients

  • Han, Hee Ji;Kim, Ju Ree;Nam, Hee Rim;Keum, Ki Chang;Suh, Chang Ok;Kim, Yong Bae
    • Radiation Oncology Journal
    • /
    • 제32권3호
    • /
    • pp.132-137
    • /
    • 2014
  • Purpose: To evaluate non-sentinel lymph node (LN) status after sentinel lymph node biopsy (SNB) in patients with breast cancer and to identify the predictive factors for disease failure. Materials and Methods: From January 2006 to December 2007, axillary lymph node (ALN) dissection after SNB was performed for patients with primary invasive breast cancer who had no clinical evidence of LN metastasis. A total of 320 patients were treated with breast-conserving surgery and radiotherapy. Results: The median age of patients was 48 years, and the median follow-up time was 72.8 months. Close resection margin (RM) was observed in 13 patients. The median number of dissected SNB was two, and that of total retrieved ALNs was 11. Sentinel node accuracy was 94.7%, and the overall false negative rate (FNR) was 5.3%. Eleven patients experienced treatment failure. Local recurrence, regional LN recurrence, and distant metastasis were identified in 0.9%, 1.9%, and 2.8% of these patients, respectively. Sentinel LN status were not associated with locoregional recurrence (p > 0.05). Close RM was the only significant factor for disease-free survival (DFS) in univariate and multivariate analysis. The 5-year overall survival, DFS, and locoregional DFS were 100%, 96.8%, and 98.1%, respectively. Conclusion: In this study, SNB was performed with high accuracy and low FNR and high locoregional control was achieved.

Comparison of WHO and RECIST Criteria for Evaluation of Clinical Response to Chemotherapy in Patients with Advanced Breast Cancer

  • Khokher, Samina;Qureshi, Muhammad Usman;Chaudhry, Naseer Ahmad
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제13권7호
    • /
    • pp.3213-3218
    • /
    • 2012
  • When patients with advanced breast cancer (ABC) are treated with neoadjuvant chemotherapy (NACT), efficacy is monitored by the extent of tumor shrinkage. Since their publication in 1981, World Health Organization (WHO) guidelines have been widely practiced in clinical trials and oncologic practice, for standardized tumor response evaluation. With advances in cancer treatment and tumor imaging, a simpler criterion based on one-dimensional rather than bi-dimensional (WHO) tumor measurement, named Response Evaluation Criteria in Solid Tumors (RECIST) was introduced in 2000. Both approaches have four response categories: complete response, partial response, stable disease and progressive disease (PD). Bi-dimensional measurement data of 151 patients with ABC were analysed with WHO and RECIST criteria to compare their response categories and inter criteria reproducibility by Kappa statistics. There was 94% concordance and 9/151 patients were recategorized with RECIST including 6/12 PD cases. RECIST therefore under-estimates and delays diagnosis of PD. This is undesirable because it may delay or negate switch over to alternate therapy. Analysis was repeated with a new criteria named RECIST-Breast (RECIST-B), with a lower threshold for PD (${\geq}10%$ rather than ${\geq}20%$ increase of RECIST). This showed higher concordance of 97% with WHO criteria and re-categorization of only 4/151 patients (1/12 PD cases). RECIST-B criteria therefore have advantages of both ease of measurement and calculations combined with excellent concordance with WHO criteria, providing a practical clinical tool for response evaluation and offering good comparison with past and current clinical trials of NACT using WHO guidelines.

Survival Rate of Breast Cancer Patients In Malaysia: A Population-based Study

  • Abdullah, Nor Aini;Mahiyuddin, Wan Rozita Wan;Muhammad, Nor Asiah;Ali, Zainudin Mohamad;Ibrahim, Lailanor;Tamim, Nor Saleha Ibrahim;Mustafa, Amal Nasir;Kamaluddin, Muhammad Amir
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제14권8호
    • /
    • pp.4591-4594
    • /
    • 2013
  • Breast cancer is the most common cancer among Malaysian women. Other than hospital-based results, there are no documented population-based survival rates of Malaysian women for breast cancers. This populationbased retrospective cohort study was therefore conducted. Data were obtained from Health Informatics Centre, Ministry of Health Malaysia, National Cancer Registry and National Registration Department for the period from $1^{st}$ January 2000 to $31^{st}$ December 2005. Cases were captured by ICD-10 and linked to death certificates to identify the status. Only complete data were analysed. Survival time was calculated from the estimated date of diagnosis to the date of death or date of loss to follow-up. Observed survival rates were estimated by Kaplan-Meier method using SPSS Statistical Software version 17. A total of 10,230 complete data sets were analysed. The mean age at diagnosis was 50.6 years old. The overall 5-year survival rate was 49% with median survival time of 68.1 months. Indian women had a higher survival rate of 54% compared to Chinese women (49%) and Malays (45%). The overall 5-year survival rate of breast cancer patient among Malaysian women was still low for the cohort of 2000 to 2005 as compared to survival rates in developed nations. Therefore, it is necessary to enhance the strategies for early detection and intervention.

40대 유방암 생존자의 우울·불안 위험요인 (Risk Factors for Depression and Anxiety among Breast Cancer Survivors in Their 40s)

  • 황숙연
    • 한국콘텐츠학회논문지
    • /
    • 제15권2호
    • /
    • pp.313-323
    • /
    • 2015
  • 본 연구는 우리나라에서 가장 유방암 발생률이 높은 40대 유방암 생존자들의 우울과 불안의 정도를 파악하고 그 위험요인들을 검토하기 위해 수행되었다. 자료 수집은 유방암으로 진단 받은 40-49세 유방암 생존자 중 연구에 동의하고 설문지를 완성한 609명을 대상으로 이루어졌다. CES-D와 GAD-7을 사용하여 측정된 우울과 불안의 평균점수는 각각 16.35(SD=9.24), 4.25(SD=4.17)였으며, 절단점을 기준으로 우울군은 전체의 47.7%, 불안군은 10.3%로 나타났다. BPI-K로 측정된 통증강도 평균은 1.91(SD=1.60)이었으며, 전체의 82.8%가 통증을 호소하였고 10.9%가 중증도 이상의 통증을 보고하였다. 위계적 회귀분석결과 최종모델에서 통증 일상생활방해정도, 직업 없음, 동거가족유형과 과거 정신과 질환이 우울의 유의미한 위험요인으로 나타났고, 불안의 위험요인은 통증 일상생활방해정도, 직업 없음 및 과거 정신과질환으로 나타났다. 이러한 결과는 우리나라 40대 유방암 생존자의 우울과 불안 유병률이 높으며, 우울과 불안의 위험요인에 초점을 두어 위험군에 대한 적절한 심리사회적 개입이 제공되어야 함을 지적해주고 있다.

Suppression of Metastasis of Human Breast Cancer Cells by Chitosan Oligosaccharides

  • Nam, Kyung-Soo;Shon, Yun-Hee
    • Journal of Microbiology and Biotechnology
    • /
    • 제19권6호
    • /
    • pp.629-633
    • /
    • 2009
  • The present study investigated the antimetastatic property of chitosan oligosaccharides (COS) by evaluating motility, invasion, and the amount and activity of MMP-9 in MDA-MB-231 human breast carcinoma cells. Treatment of MDA-MB-231 cells with increasing concentrations of COS led to a concentration-dependent decrease in cell migration. COS significantly inhibited the invasion of MDA-MB-231 cells through a Matrigel-coated membrane. The treatment of MDA-MB-231 cells with COS reduced the amounts of secreted MMP-9. The activity and amount of MMP-9 protein in MDA-MB-231 cells were decreased by treatment with COS and occurred in a concentration-dependent manner. Our data indicated that COS can serve as a potential novel therapeutic candidate for the treatment of metastatic breast cancer.

유방암 환자의 증상 클러스터 (Symptom Clusters in Patients with Breast Cancer)

  • 김수현;이란;이건숙
    • 성인간호학회지
    • /
    • 제21권6호
    • /
    • pp.705-717
    • /
    • 2009
  • Purpose: The purpose of this study was to identify symptom clusters in patients with breast cancer and to investigate the associations among them with functional status and quality of life (QOL). Methods: A convenient sample of 303 patients was recruited from an oncology-specialized hospital. Results: Two distinct clusters were identified: A gastrointestinal- fatigue cluster and a pain cluster. Each cluster significantly influenced functional status and QOL. Based on these two clusters, we identified subgroups of symptom clusters using K-means cluster analysis. Three relatively distinct patient subgroups were identified in each cluster: mild, moderate, and severe group. Disease-related factors (i.e., stage, metastasis, type of surgery, current chemotherapy, and anti-hormone therapy) were associated with these subgroups of symptom clusters. There were significant differences in functional status and QOL among the three subgroups. The subgroup of patients who reported high levels of symptom clusters reported poorer functional status and QOL. Conclusion: Clinicians can anticipate that breast cancer patients with advanced stage, metastasis, and who receive mastectomy, and chemotherapy will have more intense gastrointestinal-fatigue or pain symptoms. In order to enhance functional status and QOL for patients with breast cancer, collective management for symptoms in a cluster may be beneficial.

  • PDF